Overview
- 11 FDA inspections are on record.
- 7 inspections produced a Form 483.
- The most recent recorded inspection date is 2026-02-27.
At a glance
Inspections
11
Form 483s
7
EIRs
0
Last outcome
Form 483
Inspection history
FDA inspections on record, most recent first.
| Inspection | Category | Outcome | Form 483 |
|---|---|---|---|
| 19 Feb 2026 – 27 Feb 2026 | Human Drugs | 483 | On file |
| 12 Apr 2022 – 15 Apr 2022 | Human Drugs | Clean | |
| 14 Nov 2019 – 22 Nov 2019 | Human Drugs | 483 | On file |
| 18 Feb 2019 – 22 Feb 2019 | Human Drugs | 483 | View 483 → |
| 8 Oct 2018 – 16 Oct 2018 | Human Drugs | 483 | View 483 → |
| 22 Jan 2018 – 25 Jan 2018 | Human Drugs | Clean | |
| 7 Dec 2017 – 13 Dec 2017 | Human Drugs | 483 | On file |
| 6 Dec 2017 – 11 Dec 2017 | Human Drugs | Clean | |
| 10 Aug 2015 – 14 Aug 2015 | Human Drugs | 483 | On file |
| 3 Aug 2015 – 7 Aug 2015 | Human Drugs | Clean | |
| 19 Aug 2013 – 23 Aug 2013 | Human Drugs | 483 | On file |
Observations on record
Form 483 observations cited at this site, most recent first.
16 Oct 2018
21 CFR 211.186(b)(7)
Theoretical yield statement including percentages
Cited by Angela E Glenn
16 Oct 2018
21 CFR 211.186(b)(7)
Theoretical yield statement including percentages
Cited by Angela E Glenn
Investigators
FDA investigators tied to this site in the record.
Eileen A Liu1 insp.
Ashar P Parikh1 insp.
Gene R Gunn1 insp.
Taichun Qin1 insp.
Tiara N Brown-Crosen1 insp.
Angela E Glenn1 insp.
Susanne M Richardson1 insp.
Roger F Zabinski1 insp.
Yvins Dezan1 insp.
Arindam Dasgupta1 insp.
Young M Choi1 insp.
Ademola O Daramola1 insp.
Nebil A Oumer1 insp.
Myra K Casey1 insp.
Peter E Baker1 insp.
Recurring citations
CFR citation patterns observed across this site's inspections.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 211.110(a) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.186(b)(7) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.25(a) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.63 | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 314.80(b) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 310.305(a) | Cited across public-safe Form 483 observations | 1x |
Full site report
Get the verbatim findings behind Reliance Life Sciences Private Limited's 7 Form 483s
Verbatim observations and recurring CFR citations, so your team knows what this site gets cited for.
- The site's full inspection history, with every Form 483 and its outcome
- Warning letters and recalls tied to the company behind it
- Whether recurring CFR citations get closed out or repeat